Skip to main content

Table 1 Patient characteristics

From: Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

Characteristics

(n = 88)

Age (years, mean ± SD)

69.4 ± 8.8

Sex, n (%)

 male

74 (84)

 female

14 (16)

Smoking status, n (%)

 never smoker

10 (11)

 smoker (current or former)

78 (89)

ECOG PS, n (%)

 0–1

75 (85)

 2–4

13 (15)

Histology, n (%)

 Squamous

24 (27)

 Non-squamous

64 (73)

Stage, n (%)

 III B

21 (24)

 IV

67 (76)

EGFR, n (%)

 mutant

3 (3)

 wild type

78 (89)

 not investigated

7 (8)

ALK, n (%)

 rearranged

0

 not rearranged

80 (91)

 not investigated

8 (9)

Number of metastatic organs, n (%)

  < 3

72 (82)

  ≥ 3

16 (18)

Metastatic organs, n (%)

 Pleural effusion or dissemination

21 (24)

 Bone

26 (30)

 Brain

11 (13)

 Adrenal grand

14 (16)

 Liver

14 (16)

  1. ALK anaplastic lymphoma kinase, ECOG PS Eastern Cooperative Oncology Group performance status, EGFR epidermal growth factor receptor, SD standard deviation